Global Stroke Market Segmentation By Type (Ischemic Stroke, Transient Ischemic Attack (TIA), and Hemorrhage Stroke), Treatment (Medication, Surgery, and Other Therapy), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Gender (Female and Male), End User (Hospitals & Clinics, Specilaty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories, and Others), Distribution Channel (Direct, Retail and Online) – Industry Trends and Forecast to 2031
Stroke Market Analysis
The global stroke market is witnessing significant growth due to increasing awareness of stroke prevention and advancements in treatment options. Stroke, a leading cause of disability and mortality worldwide, has prompted healthcare systems to focus on early diagnosis, effective treatment, and rehabilitation. Recent developments in the market include the introduction of innovative therapies, such as thrombectomy devices and advanced imaging techniques, which enable quicker and more accurate diagnosis and intervention. For instance, the FDA's approval of the Penumbra 5 MAX aspiration system has enhanced the efficacy of mechanical thrombectomy procedures for ischemic stroke patients. In addition, the integration of telemedicine has revolutionized patient management, allowing for remote monitoring and consultation, which is particularly beneficial in rural areas where access to specialized care may be limited. Moreover, initiatives aimed at educating the public about stroke symptoms and risk factors are also contributing to early detection and treatment, further driving market growth.
Stroke Market Size
The global stroke market size was valued at USD 32.57 billion in 2023 and is projected to reach USD 58.09 billion by 2031, with a CAGR of 7.50% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Stroke Market Trends
“Rising Adoption of Telemedicine for Stroke Care”
The global stroke market is witnessing significant growth due to increasing awareness of stroke prevention and advancements in treatment options. A significant trend in the stroke market is the increasing adoption of telemedicine for stroke care, which enhances timely diagnosis and treatment. Telemedicine allows healthcare providers to conduct remote consultations, enabling quick assessments of patients experiencing stroke symptoms. This approach has proven crucial, particularly in rural or underserved areas where access to specialized stroke care may be limited. For instance, the TeleStroke program implemented by various healthcare institutions allows neurologists to evaluate patients via video conferencing, ensuring that critical care decisions can be made within the crucial "golden hour" following a stroke onset. This timely intervention is essential for administering thrombolytic therapy, which can significantly improve patient outcomes. As technology continues to evolve, the integration of telemedicine in stroke management streamlines treatment processes and enhances patient engagement and education, ultimately contributing to better recovery rates and reduced healthcare costs in the stroke market.
Report Scope and Stroke Market Segmentation
|
Attributes
|
Stroke Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Boehringer Ingelheim International GmbH (Germany), Sanofi (France), Bristol-Myers Squibb Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (Ireland), Teva Pharmaceuticals USA, Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Viatris Inc. (U.S.), Lupin (India), Abbott (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Penumbra, Inc. (U.S.), Oxford Laboratories Pvt. Ltd. (India), Sandoz Group AG (Switzerland), GLENMARK PHARMACEUTICALS LTD. (India), Fresenius SE & Co. KGaA (Germany), and Amneal Pharmaceuticals LLC (U.S.)
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Stroke Market Definition
A stroke, also known as a cerebrovascular accident (CVA), occurs when the blood supply to a part of the brain is interrupted or reduced, preventing brain tissue from receiving oxygen and nutrients. This disruption can be caused by either a blockage of blood vessels (ischemic stroke) or the rupture of a blood vessel (hemorrhagic stroke). The lack of blood flow can lead to brain cell death within minutes, resulting in varying degrees of disability, depending on the affected brain region and the duration of the interruption.
Stroke Market Dynamics
Drivers
- Increasing Incidence of Stroke
The increasing incidence of stroke is a pressing global health issue, with statistics showing that approximately 15 million people worldwide suffer a stroke each year, according to the World Health Organization (WHO). This rise can be largely attributed to aging populations, as the risk of stroke increases with age, particularly in individuals over 65. In addition, lifestyle changes, including sedentary behavior, poor diet, and smoking, have led to a surge in risk factors such as hypertension, diabetes, and obesity. As a result, the growing number of stroke cases is significantly driving demand for effective treatments, rehabilitation therapies, and advanced diagnostic tools to enhance patient outcomes and reduce the overall burden of this debilitating condition, driving the market growth.
- Rising Prevalence of Hypertension and Coronary Heart Disease Patients
Hypertension, often referred to as high blood pressure, is a medical condition marked by an increased force of blood exerted against the artery walls. Coronary heart disease (CHD), also known as coronary artery disease, develops from the gradual buildup of fatty deposits (atherosclerosis) in the coronary arteries, which deliver essential oxygen and nutrients to the heart muscle. There is a close connection between stroke and the rising prevalence of hypertension and CHD, as they share common risk factors and underlying physiological mechanisms. Specifically, high blood pressure significantly heightens the risk of stroke by damaging blood vessels and increasing the likelihood of blood clot formation. Chronic hypertension can lead to atherosclerosis, resulting in the narrowing of blood vessels and reduced blood flow to the brain, which in turn escalates the risk of both ischemic strokes (caused by blockages) and hemorrhagic strokes (caused by bleeding). In addition, elevated blood pressure can compromise the integrity of blood vessels in the brain, making them more susceptible to rupture or blockage, thereby further increasing the risk of stroke. As the prevalence of hypertension and CHD rises, the demand for effective stroke prevention and treatment options will continue to grow, driving the market for innovative diagnostic tools and therapeutic interventions.
Opportunities
- Increasing Development of Novel Therapies
The development of novel therapies represents a significant market opportunity in the stroke treatment space, as ongoing R&D in pharmaceuticals continues to advance. Key areas of focus include neuroprotective agents that aim to protect brain cells during and after a stroke, stem cell therapies that promote brain tissue regeneration, and innovative clot-busting drugs such as new-generation tissue plasminogen activators (tPA) that work more effectively within a broader treatment window. For instance, the advancement of stem cell-based therapies, such as MultiStem developed by Athersys, has shown promise in promoting neurological recovery by reducing inflammation and protecting damaged neurons, particularly in ischemic stroke patients. These novel approaches address unmet medical needs and create new avenues for pharmaceutical companies to capture market share, especially as these therapies move from clinical trials toward commercial availability. This growing pipeline of innovative treatments is anticipated to significantly expand the stroke treatment market as demand for more effective and less invasive options increases globally.
- Increasing Advancements in Technology
Advancements in technology present substantial opportunities for companies in the stroke market to improve treatment and management through the development of innovative medical devices and tools. For instance, thrombectomy devices, which are designed to remove blood clots from the brain, have revolutionized acute stroke care, enabling faster and more effective interventions that can dramatically reduce the risk of long-term disability. In addition, AI-powered diagnostic tools are emerging as crucial assets in stroke detection, providing rapid and accurate analysis of imaging data, which can facilitate timely decision-making. Companies such as Medtronic and Penumbra are leading the way with their advanced thrombectomy devices that have significantly improved patient outcomes. The integration of Such technologies enhances clinical efficacy and positions companies to capture a larger share of the growing stroke treatment market, making this technological advancement a key market opportunity for innovation and competitive advantage.
Restraints/Challenges
- Managing Stroke in Patients with Multiple Chronic Conditions
Managing stroke in patients with multiple chronic conditions poses significant challenges, as these concurrent health issues can complicate both treatment and recovery. One major complication arises from polypharmacy and medication interactions, where patients with multiple chronic conditions often require numerous medications. This situation increases the risk of drug interactions and adverse effects, making medication management particularly complex in stroke care. For instance, the use of anticoagulants or antiplatelet medications requires careful consideration to balance the risks of bleeding and clotting. As the prevalence of stroke patients with multiple chronic conditions rises, the complexities associated with polypharmacy present a notable market challenge, highlighting the need for innovative solutions to ensure safe and effective medication management.
- Significant Expenses Related to Stroke Treatment
The substantial costs associated with stroke treatment represent a significant concern within the healthcare landscape, affecting both patients and healthcare systems. The initial phase of stroke care entails emergency medical services, including ambulance transport, emergency room assessments, and diagnostic imaging such as CT scans and MRIs. The urgent nature and complexity of these services contribute to escalating expenses. As a result, the high financial burden of stroke treatment poses a considerable market challenge, hampering the overall development of the market.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Stroke Market Scope
The market is segmented on the basis of type, treatment, diagnosis, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Ischemic Stroke
- Transient Ischemic Attack (TIA)
- Hemorrhage Stroke
Treatment
- Medication
- Surgery
- Other Therapy
Diagnosis
- Imaging Test
- Blood Test
- Echocardiogram
- Lumbar Puncture
- Other
Gender
- Female
- Male
End User
- Hospitals & Clinics
- Specialty Clinics
- Ambulatory Surgical Centers
- Homecare
- Laboratories
- Others
Distribution Channel
- Direct
- Retail
- Online
Stroke Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, end user, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is anticipated to lead the stroke market, driven by its strong presence of major industry players and its status as the largest consumer market with a high GDP. The region benefits from substantial investments in healthcare innovation and advanced medical technologies. The U.S., in particular, is set to dominate the North American market due to its continuous advancements in stroke-related products and cutting-edge treatment options, further boosting the market's growth potential.
Germany is expected to lead the European market, primarily due to the strong presence of key industry players and its well-established healthcare infrastructure. This strategic position allows Germany to drive innovation and growth in the region, further solidifying its market dominance.
China is anticipated to dominate the Asia-Pacific region, driven by the rising incidence of stroke and a growing demand from emerging markets. In addition, China's ongoing healthcare expansion and investments in medical advancements further strengthen its position in the regional market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Stroke Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Stroke Market Leaders Operating in the Market Are:
- Bayer AG (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Boehringer Ingelheim International GmbH (Germany)
- Sanofi (France)
- Bristol-Myers Squibb Company (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Medtronic (Ireland)
- Teva Pharmaceuticals USA, Inc. (U.S.)
- Pfizer Inc. (U.S.)
- AstraZeneca (U.K.)
- Viatris Inc. (U.S.)
- Lupin (India)
- Abbott (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Penumbra, Inc. (U.S.)
- Oxford Laboratories Pvt. Ltd. (India)
- Sandoz Group AG (Switzerland)
- GLENMARK PHARMACEUTICALS LTD. (India)
- Fresenius SE & Co. KGaA (Germany)
- Amneal Pharmaceuticals LLC (U.S.)
Latest Developments in Stroke Market
- In October 2024, Siemens Healthineers announced its collaboration with over 20 industry and public partners, including seven prominent stroke hospitals, to enhance stroke management for patients throughout Europe. The five-year 'UMBRELLA' project, with a total budget of USD 29.30 million, is being funded in part by the Innovative Health Initiative (IHI), a public-private partnership aimed at health research and innovation between the European Union and the life sciences sector in Europe, as well as contributions from industry partners involved in the consortium
- In September 2024, Michigan-based medical device leader Stryker has finalized its acquisition of the Nico Corporation to enhance its neurotechnology and stroke care portfolio. This acquisition includes systems specifically designed for managing surgeries to treat intracerebral hemorrhages (ICH), known as BrainPath and Myriad. By integrating Nico's innovative technologies, Stryker aims to strengthen its offerings in the neurotechnology sector and improve treatment options for patients suffering from stroke-related conditions
- In August 2024, Christian Medical College (CMC) Vellore and IIT Madras unveiled a portable robotic device called PLUTO (Plug-and-Train Robot for Hand Neurorehabilitation) aimed at assisting stroke survivors in their recovery through hand movement therapy. This innovative device is crafted to be both affordable and user-friendly, ensuring accessibility for use in diverse environments such as hospitals, small clinics, community centers, and even at home
- In February 2024, Basking Biosciences, a clinical-stage biopharmaceutical company focused on developing an innovative acute thrombolytic therapy for stroke treatment, announced the completion of a USD 55 million financing round. The round was led by new investor ARCH Venture Partners, with contributions from other new investors including Insight Partners, Platanus, Solas BioVentures, and RTW Investments, alongside existing investors Longview Ventures, Rev1 Ventures, and The Ohio State University
- In May 2022, researchers at Osaka Metropolitan University began exploring robotic therapy as a promising treatment for stroke recovery during its chronic stage. If widely adopted, robotic therapy could enhance stroke patient care by offering a cost-effective solution with minimal need for direct supervision from therapeutic staff
- In April 2022, the U.S. National Institutes of Health (NIH) provided USD 1.8 million in funding for a project aimed at developing artificially grown, simplified mini-organs. These brain-like miniature organs are intended to produce particles that could be harvested for creating new medications targeting brain cells damaged by stroke
SKU-